Key Points - Company Grinda plans to invest 80 million yuan to subscribe for 1.91% of Muxi's initial public offering shares [1] - Fuyong Technology clarifies that its products do not possess AI capabilities [1] - Bohui Paper Industry intends to invest 1.7 billion yuan to establish a project with an annual production capacity of 320,000 tons of chemical pulp [1] - Jinggong Technology has won the bid for the Wuhan Qingshan high-performance carbon fiber production base project [1] - Yonghe Intelligent Control plans to transfer 100% equity and debt of its wholly-owned subsidiary Chengdu Shanshui [2] - Zhigang Home plans to repurchase shares with an investment of 80 million to 110 million yuan [2] - Meikailong's shareholder Hangzhou Haoyue intends to reduce its holdings by no more than 131 million shares [2] - International Medical plans to raise no more than 1.008 billion yuan through a private placement [2] - Guizhou Bailin's actual controller Jiang Wei has received a notice of investigation from the Securities Regulatory Commission [2]

Group 1 - Dongfang Electric announced that three executives plan to reduce their holdings by a total of no more than 30,000 shares due to personal financial needs [1] - Yahu Pharmaceutical's APL-1401 clinical trial data was presented at the 19th European Colorectal Congress, indicating progress in treating moderate to severe ulcerative colitis [1] - Guizhou Bai Ling's actual controller is under investigation by the China Securities Regulatory Commission for insider trading and information disclosure violations [3] Group 2 - Bairen Medical's ePTFE pericardial membrane product has been approved for registration, ending the reliance on imports for this product in the domestic market [4] - Qianxin received approval for a total of 2 billion yuan in technology innovation bonds, with plans to issue medium-term notes and short-term financing bonds [6] - Tengjing Technology's shareholder plans to reduce holdings by no more than 1.96% of the company's shares [7] Group 3 - Yuntianhua's subsidiary is required to pay 386 million yuan in overdue taxes and penalties, which will impact the company's net profit for 2025 [8] - Jianyou Pharmaceutical's propofol emulsion injection has received FDA approval in the United States [9] - Suzhou Gaoxin successfully acquired land use rights for a residential project for 360 million yuan [9] Group 4 - Chalco International's subsidiary won a bid for a 3.03 billion yuan electrolytic aluminum project [11] - Tai Long Pharmaceutical's stock will continue to be suspended due to potential changes in control as the major shareholder is planning a share transfer [12] - Qianli Technology reported a 63.44% year-on-year increase in automobile sales for November, although new energy vehicle sales decreased by 43.98% [13] Group 5 - Fosun Pharma's innovative drug FXS0887 has received approval for a Phase I clinical trial for advanced malignant solid tumors [14] - Guoen Co. has obtained approval for a project to produce 20,000 square meters of aviation-grade acrylic glass, with a total investment of 560 million yuan [15] - Guofa Co.'s chairman resigned due to personal reasons [17] Group 6 - Shanghai Construction won a bid for a state-owned construction land use right for 264 million yuan [18] - Weixin Kang's subsidiary received approval for a clinical trial of lidocaine cream for local anesthesia [20] - Sanxing Medical's subsidiary is a candidate for a 152 million yuan transformer procurement project for the State Grid [20] Group 7 - People's Daily announced the resignation of its president due to work changes, while retaining other leadership roles [21] - Beibu Gulf Port reported a 0.29% year-on-year increase in cargo throughput for November [22] - Chongqing Construction won three engineering projects with a total value of approximately 2.773 billion yuan [23] Group 8 - Xingyu Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [24] - Huajian Group signed a design contract worth 160 million yuan for a comprehensive project [25] - Wankai New Materials plans to invest 350 million yuan in a technical transformation project for producing 100,000 tons of adipic acid [26] Group 9 - Kaipuyun received a government subsidy of 18 million yuan, which is 87.43% of its net profit for the last audited fiscal year [28] - Ningbo Port expects a 10.8% year-on-year increase in container throughput for November [30] - An Cai High-Tech plans to invest 498 million yuan to upgrade its photovoltaic glass production line [32] Group 10 - Shunhao Co. stated that its existing business has not generated synergies with the rail business, which faces various risks [34] - Yihualu plans to publicly transfer 35% of its stake in Liaoyun Company [35] - ST Wanfang's shareholder plans to reduce holdings by no more than 3% of the company's shares [36] Group 11 - Youyou Food's shareholder plans to reduce holdings by no more than 110,000 shares [38] - Hengtong Optic-Electric's incentive fund has spent 49.98 million yuan to purchase company shares [41] - Zoli Pharmaceutical plans to issue convertible bonds to raise no more than 1.556 billion yuan for various projects [42]

（记者 曾健辉） 每经AI快讯，重庆建工12月3日晚间发布公告称，近日，重庆建工集团股份有限公司分别与重庆高速巨 能建设集团有限公司、中电建十一局（重庆）建设有限公司组建联合体，收到八横线白市驿隧道至黄桷 坪长江大桥段工程施工一标段和快速路五联络线椿萱大道春华立交至空港东路立交段施工的两份中标通 知书，确认以上两个联合体分别中标八横线项目和五联络线项目等两个项目。其中，重庆建工在两个项 目中承建的工程体量合计约为19.75亿元（具体金额以正式合同为准）。 每经头条（nbdtoutiao）——股民发帖求主力拉涨停，次日竟成真！襄阳轴承涨停迷局背后：平台审核 漏洞与市场操纵疑云发酵 ...

智通财经APP讯，重庆建工(600939.SH)发布公告，公司分别与巨能集团、中电十一局组建联合体，中 标八横线白市驿隧道至黄桷坪长江大桥段工程施工一标段和快速路五联络线椿萱大道春华立交至空港东 路立交段施工项目。其中公司在两个项目中承建的工程体量合计约为19.75亿元。 ...

| 转债代码：110064 | 转债简称：建工转债 | | | | | --- | --- | --- | --- | --- | | 证券代码：600939 债券代码：254104 | 证券简称：重庆建工 债券简称：24 渝建 | 01 | 公告编号：临 | 2025-116 | 重庆建工集团股份有限公司 关于工程项目中标的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●风险提示：截至本公告日，中标项目尚未签订正式合同，合同 条款尚存在不确定性，具体内容以最终签署的合同为准。项目工期较 长，预计对重庆建工集团股份有限公司（以下简称"公司"）当期营业 收入、利润影响有限。敬请广大投资者注意投资风险。 近日，公司之全资子公司重庆建工第三建设有限公司（以下简称 "三建公司"）和中国建筑第六工程局有限公司（以下简称"中建六 局"）组建联合体，收到快速路五联络线宝山大桥西延伸段（渝武高 速至江家坪立交）施工项目的中标通知书，确认其中标该项目。其中， 三建公司承建的工程体量约 7.975 亿元（具体金额以正 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●风险提示：截至本公告日，中标项目尚未签订正式合同，合同 条款尚存在不确定性，具体内容以最终签署的合同为准。项目工期较 长，预计对公司当期营业收入、利润影响有限。敬请广大投资者注意 投资风险。 | 证券代码：600939 | 证券简称：重庆建工 | | 公告编号：临 | 2025-117 | | --- | --- | --- | --- | --- | | 转债代码：110064 | 转债简称：建工转债 | | | | | 债券代码：254104 | 债券简称：24 | 渝建 01 | | | 重庆建工集团股份有限公司 关于工程项目中标的公告 项目工期：1,460 日历天 二、联合体基本信息 近日，重庆建工集团股份有限公司（以下简称"公司"或"重庆 建工"）分别与重庆高速巨能建设集团有限公司（以下简称"巨能集 团"）、中电建十一局（重庆）建设有限公司（以下简称"中电十一 局"）组建联合体，收到八横线白市驿隧道至黄桷坪长江大桥段工程 施工一标段（以下简称"八 ...

格隆汇12月3日丨重庆建工(600939.SH)公布，近日，公司之全资子公司三建公司和中建六局组建联合 体，收到快速路五联络线宝山大桥西延伸段（渝武高速至江家坪立交）施工项目的中标通知书，确认其 中标该项目。中标价：14.50亿元。其中，三建公司承建的工程体量约7.975亿元（具体金额以正式合同 为准）。 ...

重庆建工12月3日公告，公司之全资子公司重庆建工第三建设有限公司与中国建筑第六工程局有限公司 组成的联合体收到快速路五联络线宝山大桥西延伸段（渝武高速至江家坪立交）施工项目的中标通知 书，中标价14.4997亿元。其中，三建公司承建的工程体量约7.975亿元。项目工期为1260日历天，预计 对公司当期营业收入、利润影响有限。 ...

另外，公司全资子公司三建公司和中建六局组建联合体，中标快速路五联络线宝山大桥西延伸段（渝武 高速至江家坪立交）施工项目，其中三建公司承建的工程体量约7.975亿元。 转自：证券时报 人民财讯12月3日电，重庆建工(600939)12月3日公告，公司分别与巨能集团、中电十一局组建联合体， 中标八横线白市驿隧道至黄桷坪长江大桥段工程施工一标段和快速路五联络线椿萱大道春华立交至空港 东路立交段施工项目。其中公司在两个项目中承建的工程体量合计约为19.75亿元。 ...

Core Insights - Chongqing Construction (600939.SH) has recently formed joint ventures with Juneng Group and China Electric Power Equipment and Technology Co., Ltd. to secure two construction projects [1] - The projects include the construction of the section from Baixiang Line's Baishi Yizhong Tunnel to Huangjueping Yangtze River Bridge and the section from Chuanxuan Avenue to Konggang East Road Interchange of the Rapid Road Five Connection Line [1] - The total engineering volume for Chongqing Construction in these two projects is approximately 1.975 billion yuan, subject to formal contract confirmation [1] Project Details - The joint ventures have received bid notifications for the Baixiang Line and Rapid Road projects [1] - The specific segments of the projects involve significant infrastructure development in Chongqing [1] - The financial implications of these projects are substantial, with a combined value of around 1.975 billion yuan [1]